Clinical Trials Logo

Liver Metastases clinical trials

View clinical trials related to Liver Metastases.

Filter by:

NCT ID: NCT03678428 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

Start date: October 31, 2018
Phase: Phase 3
Study type: Interventional

The aim of the trial is to compare the objective response rates of FUDR/Oxaliplatin HAI plus CPT-11 and FOLFOXIRI chemotherapy in patients with initially non-resectable metastatic colorectal cancer liver metastases. The patients will be treated with systemic FOLFOXIRI chemotherapy or FUDR/Oxaliplatin hepatic arterial infusion with CPT-11 systemic chemotherapy.

NCT ID: NCT03654131 Recruiting - Liver Metastases Clinical Trials

Stereotactic Body Radiation Therapy vs. Percutaneous Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver

Start date: July 25, 2018
Phase: Phase 2
Study type: Interventional

This study is a randomized phase II trial between microwave ablation (MWA) and stereotactic body radiotherapy (SBRT) - two standard treatment modalities for colorectal patients with metastatic disease in the liver. Primary endpoint is freedom form local lesion progression.

NCT ID: NCT03620916 Recruiting - Liver Cancer Clinical Trials

Comparison of Intrathecal and Intravenous Analgesia in Patients Undergoing Liver Resection

Start date: August 2018
Phase: N/A
Study type: Interventional

The aim of this prospective, interventional, randomized trial is to compare the effectiveness of postoperative analgesia using single-dose intrathecal morphine and intravenous morphine in patients undergoing liver resection. The study is to include a total 36 patients randomized in a 1:1 ratio into two groups. The study will be single-blinded with respect to outcome assessors. Patients in the experimental group (n=18) will receive a single dose (0,4 mg) intrathecal morphine immediately before operation and patient-controlled analgesia (PCA) with morphine over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4) over next two days in the postoperative period. Patients in the control group (n=18) will receive a single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation and PCA with morphine over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4) over next two days. Both groups will receive antiemetic prophylaxis with dexamethasone (4 mg) and ondansetron (4 mg) and standard baseline analgesia with paracetamol (1,0 g every 6 hours) and dexketoprofen (50 mg every 8 hours). Severity of pain at rest evaluated with numerical rating scale twice daily over 3 first postoperative days will be the primary outcome measure. Secondary outcome measures will include: severity of pain at coughing evaluated with numerical rating scale twice daily over 3 first postoperative days, total dose of morphine administered with PCA, time to patient mobilization, grade of sedation, intestinal motility, solid food intake tolerance, duration of hospitalization, and postoperative complications.

NCT ID: NCT03590119 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases

LUTIA
Start date: August 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The objective is to investigate the impact of intra-arterial administration of 177Lu-dotatate on the intrahepatic biodistribution in patients with NET liver metastases. Our primary objective is to evaluate if there is a difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.

NCT ID: NCT03532204 Not yet recruiting - Colorectal Cancer Clinical Trials

Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer

OLIVER
Start date: August 15, 2018
Phase: N/A
Study type: Interventional

The role of radiotherapy in metastatic cancer has historically been limited to palliation while metastasectomy or radiofrequency has emerged as playing a major role in disease control. Although resection is the standard of care for liver metastasis, 80-90% of patients are not resectable at diagnosis in particular because of the presence of oligometastases. Factors that favour a truly oligometastatic state include a long latent interval between the treatment of the primary tumor and the appearance of metastases. Oligometastatic cancer is a very heterogeneous disease with respect to several factors including the location of the primary tumor. With the advent of extracranial stereotactic body radiation therapy (SBRT), higher biological equivalent doses can be safely delivered in 3 to 5 fractions, thus potentially ablating all the tissue in the treated area while protecting more efficiently the hosting organ and healthy tissues surrounding the tumors. In patients with liver oligometastases, in-field local control rates at 2 years range from 70% to 90% with less than 5% severe grade 3 or higher toxicity rates. Retrospective studies indicate that roughly 20% of the patients remain disease-free 2 to 4 years after SBRT. For patients treated with SBRT some authors found that half of the patients had either no metastatic progression or very little progression in terms of number and site of metastases. The patterns of failure after SBRT for oligometastases in one organ showed that 73% of patients eventually developed new metastases with higher than 80% occurring as new metastases in the same index organ. These findings support the idea of an oligometastatic state in which aggressive local therapy could improve progression-free survival (PFS). With this phase III study, we sought to evaluate the impact of SBRT on PFS at 2 years in patients with synchronous or metachronous liver-only oligometastases from colorectal cancers patients after a first line chemotherapy for metastatic disease but not having progressed during first line chemotherapy and up to 1 year

NCT ID: NCT03518632 Recruiting - Liver Metastases Clinical Trials

Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer (APACHE)

APACHE
Start date: March 27, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to assess the impact of preoperative physical activity on physical capacities of patients undergoing liver resection for primary or secondary liver cancer.

NCT ID: NCT03507699 Not yet recruiting - Liver Metastases Clinical Trials

Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

Start date: July 1, 2018
Phase: Phase 1
Study type: Interventional

A single institution study to evaluate the safety and tolerability of the combination treatment of nivolumab, ipilimumab, CMP-001 and radiosurgery in patients with metastatic colorectal cancer with liver metastases.

NCT ID: NCT03500874 Recruiting - Colorectal Cancer Clinical Trials

Systemic Chemotherapy Plus HAI(FUDR)vs Systemic Chemotherapy Alone For CRCLM

Start date: February 28, 2018
Phase: Phase 3
Study type: Interventional

The aim of the trial is to optimize the overall survival of patients with resectable colorectal liver metastasis who have undergone liver metastasis resection. The patients will be treated with systemic chemotherapy plus hepatic arterial infusion With floxuridine, or with systemic chemotherapy only

NCT ID: NCT03494946 Recruiting - Colorectal Cancer Clinical Trials

Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer

SECAIII
Start date: December 5, 2016
Phase: N/A
Study type: Interventional

The trial is a randomized control trial. Patients are randomized between Ltx and other treatment that may include further chemotherapy, TACE, SIRT or other available treatment options. The patients will be randomized 1:1 to Ltx and chemotherapy/other treatment options.

NCT ID: NCT03493061 Recruiting - Liver Metastases Clinical Trials

A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

Start date: February 1, 2018
Phase: Phase 2
Study type: Interventional

The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis. The patients will be treated with systemic chemotherapy With irinotecan plus hepatic arterial infusion With floxuridine and oxaliplatin